Hey Anons, not sure if this is something or nothing.
Looking at the metadata on Q's fighter image, I found the document id and instance id 4A12A7DDC94CB03A7D1D94B5DB371C73
A image search in duckduckgo, throws up a wiki on Methylphenidate, otherwise known as Ritalin.
https://duckduckgo.com/?q=4A12A7DDC94CB03A7D1D94B5DB371C73&t=opera&iar=images&iax=images&ia=images&iai=http%3A%2F%2Fimages-thumbs.thefullwiki.org%2FL%2Fi%2Fs%2FLisdexamfetamine.png
My spidey senses are tingling, but I'm not sure if it's fatigue - see pics attached and clips of text below - of note is the treatment of AUTISM and also I believe that Anons know about big pharma trying to kill us and our children for a long time;
——————————————————————————————————————————————————————-
http://www.thefullwiki.org/Methylphenidate
Beginning in the 1960s, it was used to treat children with ADHD or ADD, known at the time as hyperactivity or minimal brain dysfunction (MBD). Production and prescription of methylphenidate rose significantly in the 1990s, especially in the United States, as the ADHD diagnosis came to be better understood and more generally accepted within the medical and mental health communities. [9]
Most brand-name Ritalin is produced in the United States, and methylphenidate is produced in the United States, Mexico, Argentina, and Pakistan. Other generic forms, such as "methylin", are produced by several U.S. pharmaceutical companies. Ritalin is also sold in the United Kingdom, Germany and other European countries (although in much lower volumes than in the United States). In Belgium the product is sold under the name "Rilatine" and in Brazil and Portugal as "Ritalina".
TMP is the most commonly prescribed psychostimulant and works by increasing the activity of the central nervous system. [16] It produces such effects as increasing or maintaining alertness, combating fatigue, and improving attention. [10] The benefits and cost effectiveness of methylphenidate long term are unknown due to a lack of research. [17][18] The long term effects of methylphenidate on the developing brain are unknown. Methylphenidate is not approved for children under six years of age. [19][20]
Pervasive developmental disorders
Given the high comorbidity between ADHD and autism, a few studies have examined the efficacy and effectiveness of methylphenidate in the treatment of autism. However, most of these studies examined the effects of methylphenidate on attention and hyperactivity symptoms among children with autism spectrum disorders. Aman and Langworthy (2000) attempted to examine the effects of methylphenidate on social-communication and self-regulation behaviors among kids with ASDs. [41]
The results indicate that children showed significantly more joint attention behaviors when receiving methylphenidate than when receiving the placebo (although the most effective dosage varied by individual). Furthermore, at a group level, the low dose of methylphenidate resulted in significantly improved joint attention behaviors when compared to the placebo, but no differences were noted between the low, medium, and high doses. Low and medium doses of methylphenidate also resulted in improved self-regulation behavior when compared to placebo.
The study presents compelling preliminary evidence suggesting that methylphenidate is effective in improving some social behaviors among children with autism spectrum disorders. [42]
Known or suspected risks to health
Researchers have also looked into the role of methylphenidate in affecting stature, with some studies finding slight decreases in height acceleration. [57] Other studies indicate height may normalize by adolescence. [58][59] In a 2005 study, only "minimal effects on growth in height and weight were observed" after 2 years of treatment. "No clinically significant effects on vital signs or laboratory test parameters were observed." [60]
It was documented in 2000, by Zito et al. [63][64]“that at least 1.5% of children between the ages of two and four are medicated with stimulants, anti-depressants and anti-psychotic drugs, despite the paucity of controlled scientific trials confirming safety and long-term effects with preschool children.”
On March 22, 2006 the FDA Pediatric Advisory Committee decided that medications using methylphenidate ingredients do not need black box warnings about their risks, noting that "for normal children, these drugs do not appear to pose an obvious cardiovascular risk."